Literature DB >> 11753090

Long-term renal consequences of hypertension for normal and diseased kidneys.

Anil K Bidani1, Karen A Griffin.   

Abstract

Substantial evidence indicates that the adverse effects of hypertension on the kidney depend on the degree to which systemic blood pressure elevations are transmitted to the renal microvasculature. Such blood pressure transmission and consequent susceptibility to hypertensive renal damage is markedly exacerbated in states characterized by preglomerular vasodilation and an impairment of the normally protective renal autoregulatory mechanisms, e.g. diabetes or chronic renal disease. Moreover, this pathophysiology gives rise to the prediction that prevention of hypertension-induced barotrauma will require blood pressure to be reduced well into the normotensive range in such patients, as is being recognized in the currently recommended blood pressure goals. Agents that block the renin-angiotensin system should be preferred as initial therapy as they may provide additional risk reductions and minimize the potassium and magnesium depletion associated with the diuretic use usually necessary to achieve the lower blood pressure targets. The current failure to achieve optimal blood pressure reductions may be contributing not only to the still escalating incidence of end-stage renal disease in diabetic patients, but also to their greatly increased cardiovascular morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11753090     DOI: 10.1097/00041552-200201000-00011

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  26 in total

1.  A mathematical model of the myogenic response to systolic pressure in the afferent arteriole.

Authors:  Jing Chen; Ioannis Sgouralis; Leon C Moore; Harold E Layton; Anita T Layton
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-29

Review 2.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 3.  Renal protection in hypertensive patients: selection of antihypertensive therapy.

Authors:  René R Wenzel
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression.

Authors:  Manjeri A Venkatachalam; Joel M Weinberg; Wilhelm Kriz; Anil K Bidani
Journal:  J Am Soc Nephrol       Date:  2015-03-25       Impact factor: 10.121

5.  End-organ protection in hypertension by the novel and selective Rho-kinase inhibitor, SAR407899.

Authors:  Matthias Löhn; Oliver Plettenburg; Aimo Kannt; Markus Kohlmann; Armin Hofmeister; Dieter Kadereit; Peter Monecke; Alexander Schiffer; Anke Schulte; Hartmut Ruetten; Yuri Ivashchenko
Journal:  World J Cardiol       Date:  2015-01-26

6.  Ultrafiltration Rate, Residual Kidney Function, and Survival Among Patients Treated With Reduced-Frequency Hemodialysis.

Authors:  Yu-Ji Lee; Yusuke Okuda; John Sy; Yong Kyu Lee; Yoshitsugu Obi; Seong Cho; Joline L T Chen; Anna Jin; Connie M Rhee; Kamyar Kalantar-Zadeh; Elani Streja
Journal:  Am J Kidney Dis       Date:  2019-12-06       Impact factor: 8.860

Review 7.  Acute kidney injury: a springboard for progression in chronic kidney disease.

Authors:  Manjeri A Venkatachalam; Karen A Griffin; Rongpei Lan; Hui Geng; Pothana Saikumar; Anil K Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2010-03-03

8.  Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance.

Authors:  Anil K Bidani; Maria Picken; Rifat Hacioglu; Geoffrey Williamson; Karen A Griffin
Journal:  Am J Physiol Renal Physiol       Date:  2006-09-12

Review 9.  Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be?

Authors:  Christopher A Newton; Philip Raskin
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 10.  Potential risks of calcium channel blockers in chronic kidney disease.

Authors:  Karen A Griffin; Anil K Bidani
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.